Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC/VI With or Without Temsirolimus in Intermediate Risk Rhabdomyosarcoma
NCT02567435Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2016
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of temsirolimus in rhabdomyosarcoma (RMS), sponsored by National Cancer Institute. Started Jun 2016; status: active, not recruiting.
02
Drugs
temsirolimus
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT02567435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567435.